New Key Statistics Module, Z-Score and F-Score
NAS:ARQT Key Ratios
| Market Cap $ M | 983.05 |
| Enterprise Value $ M | 821.17 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 5.22 |
| Price/Sales | 5.72 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 132.00 |
| EPS (TTM) $ | -2.19 |
| Beneish M-Score | 5.63 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -33.10 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -4.97 |
| EV-to-EBITDA | -5.02 |
| PEG | -- |
| Shares Outstanding M | 116.89 |
| Net Margin (%) | -150.51 |
| Operating Margin % | -136.13 |
| Pre-tax Margin (%) | -147.95 |
| Quick Ratio | 8.19 |
| Current Ratio | 8.46 |
| ROA % (ttm) | -52.91 |
| ROE % (ttm) | -158.44 |
| ROIC % (ttm) | -510.20 |
| Dividend Yield % | -- |
| Altman Z-Score | -0.99 |
ARQT Number of Guru Trades
ARQT Volume of Guru Trades
Gurus Latest Trades with NAS:ARQT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:ARQT is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Arcutis Biotherapeutics Inc Insider Transactions
No Available Data
News about NAS:ARQT
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers